Cancer Cachexia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Cancer Cachexia - Pipeline Review, H1 2015', provides an overview of the Cancer Cachexia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cancer Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Cachexia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cancer Cachexia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cancer Cachexia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cancer Cachexia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Cancer Cachexia Overview 9 Therapeutics Development 10 Pipeline Products for Cancer Cachexia - Overview 10 Pipeline Products for Cancer Cachexia - Comparative Analysis 11 Cancer Cachexia - Therapeutics under Development by Companies 12 Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes 15 Cancer Cachexia - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Cancer Cachexia - Products under Development by Companies 19 Cancer Cachexia - Products under Investigation by Universities/Institutes 21 Cancer Cachexia - Companies Involved in Therapeutics Development 22 Acacia Pharma Ltd. 22 Aeterna Zentaris Inc. 23 Amgen Inc. 24 Aphios Corporation 25 Atara Biotherapeutics, Inc. 26 Eli Lilly and Company 27 GTx, Inc. 28 Helsinn Healthcare S.A. 29 Incyte Corporation 30 Novartis AG 31 Ohr Pharmaceutical Inc. 32 PsiOxus Therapeutics, Ltd. 33 Radius Health, Inc. 34 RaQualia Pharma Inc. 35 Vicus Therapeutics, LLC 36 Cancer Cachexia - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Combination Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 (etodolac + propranolol hydrochloride) - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 (formoterol fumarate + megestrol acetate) - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 anamorelin hydrochloride - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 ATA-842 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 bimagrumab - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 DCB-CA2 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 dronabinol - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Drug to Antagonize ActRIIB for Cancer Cachexia - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 enobosarm - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Espindolol - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 EXT-400 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 LY-2495655 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 macimorelin acetate - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 NBD Peptide - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 OHR/AVR-118 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 RAD-140 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 RQ-00432933 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 ruxolitinib phosphate - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Small Molecule to Agonize Ghrelin Receptor for Cancer Cachexia and Anorexia - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Small Molecule to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Synthetic Peptides for Cancer Cachexia - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 VK-5211 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Cancer Cachexia - Recent Pipeline Updates 85 Cancer Cachexia - Dormant Projects 104 Cancer Cachexia - Discontinued Products 106 Cancer Cachexia - Product Development Milestones 107 Featured News & Press Releases 107 Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology 107 Dec 11, 2013: Phase II Data on OHR/AVR118 in Advanced Cancer Patients With Cachexia Presented at International Cachexia Conference in Kobe, Japan 108 Oct 24, 2013: GTx Presents Results from Enobosarm POWER Trials for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer at 15th World Conference on Lung Cancer 109 Mar 21, 2013: Ohr Pharma Announces Results From OHR/AVR118 Phase II Trial In Cancer Cachexia 110 Mar 14, 2013: GTx Announces Publication Of Enobosarm Phase II Trial Results In The Lancet Oncology 111 Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102 113 Oct 08, 2012: GTx To Present Scientific Poster Presentations On Enobosarm At International Society Of Geriatric Oncology 113 Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130 114 Jun 25, 2012: GTx Announces Presentation On Enobosarm's Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels 115 Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130 116 Appendix 117 Methodology 117 Coverage 117 Secondary Research 117 Primary Research 117 Expert Panel Validation 117 Contact Us 117 Disclaimer 118
List of Tables Number of Products under Development for Cancer Cachexia, H1 2015 10 Number of Products under Development for Cancer Cachexia - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Development by Companies, H1 2015 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2015 15 Comparative Analysis by Late Stage Development, H1 2015 16 Comparative Analysis by Clinical Stage Development, H1 2015 17 Comparative Analysis by Early Stage Development, H1 2015 18 Products under Development by Companies, H1 2015 19 Products under Development by Companies, H1 2015 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2015 21 Cancer Cachexia - Pipeline by Acacia Pharma Ltd., H1 2015 22 Cancer Cachexia - Pipeline by Aeterna Zentaris Inc., H1 2015 23 Cancer Cachexia - Pipeline by Amgen Inc., H1 2015 24 Cancer Cachexia - Pipeline by Aphios Corporation, H1 2015 25 Cancer Cachexia - Pipeline by Atara Biotherapeutics, Inc., H1 2015 26 Cancer Cachexia - Pipeline by Eli Lilly and Company, H1 2015 27 Cancer Cachexia - Pipeline by GTx, Inc., H1 2015 28 Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H1 2015 29 Cancer Cachexia - Pipeline by Incyte Corporation, H1 2015 30 Cancer Cachexia - Pipeline by Novartis AG, H1 2015 31 Cancer Cachexia - Pipeline by Ohr Pharmaceutical Inc., H1 2015 32 Cancer Cachexia - Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 33 Cancer Cachexia - Pipeline by Radius Health, Inc., H1 2015 34 Cancer Cachexia - Pipeline by RaQualia Pharma Inc., H1 2015 35 Cancer Cachexia - Pipeline by Vicus Therapeutics, LLC, H1 2015 36 Assessment by Monotherapy Products, H1 2015 37 Assessment by Combination Products, H1 2015 38 Number of Products by Stage and Target, H1 2015 40 Number of Products by Stage and Mechanism of Action, H1 2015 42 Number of Products by Stage and Route of Administration, H1 2015 44 Number of Products by Stage and Molecule Type, H1 2015 46 Cancer Cachexia Therapeutics - Recent Pipeline Updates, H1 2015 85 Cancer Cachexia - Dormant Projects, H1 2015 104 Cancer Cachexia - Dormant Projects (Contd..1), H1 2015 105 Cancer Cachexia - Discontinued Products, H1 2015 106
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.